glp-1 for diabetes GLP-1-based therapies diabetes, obesity and beyond How are GLP-1 drugs reshaping

The Rudman study famously showed an 8.8% increase in lean body mass and a 14.4% decrease in adipose tissue mass over six months of GH therapy (2)

Currently on FDA Category 2 with a PCAC review scheduled for July 2026

The content is purely informative and educational in nature and should not be construed as medical advice

administration of the compound leads to a significant reduction in body weight without a drastic caloric deficit

What it wont do is rewind the clock or take ten years off your face from a single drip

AOD 9604 Powder COA The molecular structure and chemical properties of AOD 9604 Molecular Structure AOD The chemical name of 9604 is L-phenylalanine-L-tyrosyl-L-L-leucyl-L-L-arginyl-L-Isoleucyl-L-valinyl-L-Glutamide-L-Cysteinyl-L-arginyl-L-seramide-L-valinyl-L - -glutamide-glycyryl-L-Seramide-L-cysteinylglycyryl-L (cyclic disulfide bonds are connected at positions 7-14 It has the molecular formula C78H123N23O23S2 and a molecular weight of 1815.1 Da